<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01067807</url>
  </required_header>
  <id_info>
    <org_study_id>ZP-001</org_study_id>
    <nct_id>NCT01067807</nct_id>
  </id_info>
  <brief_title>Proellex Pharmacokinetics Bridging Study</brief_title>
  <official_title>Proellex Pharmacokinetics Bridging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Healthy female subjects received a single dose of four different types of Proellex, the
      original 25 mg dose and three new formulations
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy female subjects received a single dose of four different types of Proellex, the
      original 25 mg dose and three new formulations (24 and 50 mg dose). Blood was collected
      pre-dose, at specified intervals and 24 hours post dose. Each dose was separated by at least
      one week interval from the previous dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proellex peak plasma concentration (Cmax)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proellex time to peak plasma concentration (tmax).</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The area under the plasma concentration over time curve from zero to the last measurable Proellex plasma concentration (AUC0-24) was calculated.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the plasma concentration over time curve from zero to infinity (AUC 0-infinity).</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2).</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs evaluated at screening, treatment days 0 and 1. Clinical laboratory values obtained at screening, treatment days 0 and 1. Adverse events assessed at treatment visits and followed until resolution.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Proellex Formulation 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg Proellex Gelucire and PEG (original formulation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 mg Proellex Formulation 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg Proellex coated with MCC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 mg Proellex Formulation 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg Proellex blended with MCC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg Proellex Formulation 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg Proellex blended with MCC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25 mg Proellex</intervention_name>
    <description>25 mg - given as one 25 mg capsule (252 mg of Gelucire and 88 mg of PEG400, original formulation) [Original], single dose</description>
    <arm_group_label>Proellex Formulation 1</arm_group_label>
    <other_name>CDB-4124</other_name>
    <other_name>Telapristone acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25 mg Proellex</intervention_name>
    <description>25 mg - given as one 25 mg capsule (coated with microcrystalline cellulose, new formulation) (coated), single dose</description>
    <arm_group_label>25 mg Proellex Formulation 2</arm_group_label>
    <other_name>CDB-4124</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25 mg Proellex</intervention_name>
    <description>25 mg - given as one 25 mg capsule (blended with microcrystalline cellulose, new formulation) [Blended], single dose</description>
    <arm_group_label>25 mg Proellex Formulation 3</arm_group_label>
    <other_name>CDB-4124</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mg Proellex</intervention_name>
    <description>50 mg - given as two 25 mg capsules (blended with microcrystalline cellulose, new formulation) [Blended], single dose</description>
    <arm_group_label>50 mg Proellex Formulation 3</arm_group_label>
    <other_name>CDB-4124</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medically normal subjects with no significant abnormal findings at the screening
             physical examination as evaluated by the clinical Investigator

          -  Subject was willing to remain in the clinic for the screening visit; and for the
             treatment visits (day -1, day of treatment and day 1; approximately 36 hrs per
             treatment visit)

        Exclusion Criteria:

          -  Post-menopausal women,

          -  Subject with documented endometriosis

          -  Subject with known uterine fibroids or vaginal polyps
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre van As, PhD, MD</last_name>
    <role>Study Director</role>
    <affiliation>Repros Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Healthcare Discoveries, Inc</name>
      <address>
        <city>San Antonio,</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2010</study_first_submitted>
  <study_first_submitted_qc>February 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2010</study_first_posted>
  <last_update_submitted>July 3, 2014</last_update_submitted>
  <last_update_submitted_qc>July 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

